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ackground: In many areas of Europe, double sensitization to ragweed and mugwort is common, and
ecause of the overlapping ﬂowering periods of the 2 plants, it is not possible to diagnose the primary
ensitizing allergen source and hence to determine the proper immunotherapy.
bjectives: To elucidate whether double-sensitized patients are cosensitized or cross-sensitized and, in the
latter case, to deﬁne the primary sensitizer.
Methods: Serum samples from 34 patients with late summer respiratory allergy underwent skin prick
testing with whole ragweed, and mugwort extracts were analyzed for their reactivity to recombinant Art v 1
and Amb a 1 by ImmunoCAP and then to Amb a 1, Art v 6, and Art v 1 isoforms by a proteomic approach. In
double reactors, the primary sensitizing sources were detected by inhibition experiments.
Results: Serum samples from patients monosensitized to ragweed contained IgE to epitopes speciﬁc of all
Amb a 1 isoforms. In contrast, serum samples from double reactors found to be primarily sensitized to
mugwort reacted to Art v 1 and Art v 6 and cross-reacted to a few Amb a 1 isoforms. Finally, serum samples
from double reactors found to be primarily sensitized to ragweed contained IgE reacting to all Amb a 1
isoforms, part of which cross-reacted to Art v 6. We did not ﬁnd cosensitized patients.
Conclusion: This study found that Art v 6 plays an important role in mugwort allergy and that the cross-
reactivity between Art v 6 and Amb a 1 is frequent, bidirectional, and clinically relevant in the area of Milan.
 2014 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction ﬂowering periods of these 2 Compositae plants, double sensitizationAn interesting phenomenon that is frequently observed by
clinical allergologists working in areas where both ragweed and
mugwort pollen are present is the unexpectedly high prevalence of
concomitant sensitization to these pollens. In Lombardy, where the
ragweed epidemic started in the 1980s, a marked increase in the
prevalence of mugwort sensitization has been observed in parallel
with the expansion of ragweed allergy. Notably, if individuals
sensitized to pollen pan-allergens (proﬁlin and polcalcins) are
excluded, both sensitization and allergy to mugwort in the absence
of ragweed hypersensitivity remain rare. At least 35% of ragweed-
sensitized individuals living in the surroundings of Milan have a
concomitant sensitization to mugwort on skin prick testing (SPT)
with commercial pollen extracts.1 In view of the overlappingcience Ambientali, Università di
no, Italy; E-mail: sandra.citterio@
nistry of University and Research
sthma & Immunology. Published by Erepresents a diagnostic dilemma for the clinical allergologists who
have to decide whether to prescribe 1 or 2 distinct allergen-speciﬁc
immunotherapies. These observations have prompted the consid-
eration of potential cross-reactivity, in addition to shared proﬁlin
and procalcin sensitivity, between ragweed and mugwort pollen.
More than 20 years ago, studies in the vicinity of Milan found that
distinguishing between ragweed andmugwort allergy was virtually
impossible.2,3 In vitro analyses produced contrasting results that
suggested the existence of cross-reactivity between allergens in the
2 pollen species (including themajormugwort pollen allergen, Art v
1) in some cases4 and little or no cross-reactivity in other in-
stances.5,6 More recently, one study performed with serum samples
from this area concluded that “patients showing both ragweed- and
mugwort-positive SPT and/or RAST [radioallergosorbent test] are
co-sensitized,”1 despite the percentages obtained by skin tests,
which strongly suggested a cross-reactivity (93% of mugwort-
sensitized patients had ragweed sensitization and 38% of
ragweed-allergic patients had mugwort sensitization).1
In recent years, the availability of natural puriﬁed or recombi-
nant allergen proteins for diagnostic purposes has profoundlylsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
R. Asero et al. / Ann Allergy Asthma Immunol 113 (2014) 307e313308inﬂuenced our understanding of allergic phenomena. For instance,
in patients living in northern Italy, the use of these new powerful
tools has revealed that the serum samples from 47 of 105 consec-
utive ragweed-allergic patients (45%) had IgE reactivity to Art v 1 as
well (Asero R 2012, unpublished results). Because Art v 1 has been
considered as a marker of genuine sensitization to mugwort, this
seems to conﬁrm that patients sensitized to both weeds on skin
tests are in effect cosensitized1 and should be prescribed 2 distinct
allergen extracts for immunotherapy. However, things are seem-
ingly not that simple. Leonard et al7 found that a minor ragweed
allergen, Amb a 4, is homologous to Art v 1 and demonstrated a
high degree of cross-reactivity between these 2 proteins by inhi-
bition experiments. Furthermore, they observed that many more
Austrians (who are frequently primarily allergic to mugwort) than
northern Italians (who are frequently primarily sensitized to
ragweed) react to Amb a 4 and that 42% of Art v 1esensitized pa-
tients react to Amb a 4.7 Notably, in that study Amb a 4 was
recognized by approximately 30% of serum samples from ragweed-
allergic patients, a proportion that is similar to the percentage of
ragweed-allergic patients with cosensitization to mugwort.1
Furthermore, another pair of cross-reacting allergens, Amb a 1
and Art v 6, subsequently have been detected in ragweed and
mugwort pollen, respectively.8 Although both allergens seem able
to act as primary sensitizers, it was found that Amb 1 possesses
more IgE epitopes than Art v 6 and, hence, dominates the cross-
reactivity with its mugwort counterpart.8
The clinical signiﬁcance of all these ﬁndings can be summarized
by stating that the detection of reactivity to mugwort (and even to
Art v 1) in the presence of ragweed allergy may not indicate primary
mugwort sensitivity. On the other hand, the same may hold true
if Amb a 1 hypersensitivity is found. Thus, despite the conclusions
of the former study,1 we believe that the issue of cross-reactivity
in patients with double sensitization to mugwort and ragweed
deserves to be reexamined with the new proteomic techniques.
Methods
Patients
Serum samples for this study were collected from adults with a
history of seasonal, summertime (middle of August to the end of
September) respiratory symptoms (rhinoconjunctivitis with or
without asthma) who were addressed by their family physician to
the allergy outpatient department of the Clinica San Carlo (Paderno
Dugnano, Italy) and the allergy outpatient department of the Por-
denone Hospital for allergy evaluation. All patients underwent SPT
with commercial extracts (Allergopharma, Reinbeck, Germany) of
the main seasonal airborne allergens present in Italy, including
ragweed, mugwort, grass, pellitory, plantain, birch, olive, and cy-
press, and scored positive on SPT with ragweed extract. All clinical
investigations were performed according to the principles of the
Declaration of Helsinki; all patients gave their written informed
consent to diagnostic procedures. The study was based on data
stemming from routine clinical activity and on stored serum sam-
ples previously used to perform routine clinical investigations; the
study has been approved by the institutional review board.
To avoid the interference by cross-reacting plant pan-allergens,
such as proﬁlin or calcium-binding proteins,9 only patients sensi-
tized to fewer than 3 pollens other that mugwort and/or ragweed
were ﬁnally included. Furthermore, proﬁlin hypersensitivity was
ruled out by negative commercial proﬁlin SPT results (ALK-Abellò,
Madrid Spain). Serum samples from all patients underwent the
measurement of IgE to recombinant (r) Amb a 1, the major ragweed
allergen, and those from patients with positive SPT results with
mugwort pollen extract were screened for their reactivity to rArt v
1, the major mugwort allergen. IgE were measured by the Immu-
noCAP assay (Thermo FisherePhadia, Uppsala, Sweden); levelsgreater than 0.35 kU/L were considered positive results. Serum
samples selected for immunochemical analysis were diluted 1:10 in
Tris-buffered saline with Tween 20 (TBS-T) (20-mmol/L Tris,
150-mmol/L sodium chloride, and 0.05% [vol/vol] Tween 20, pH 7.5)
and stored at 20C until use.
Preparation of Pollen Protein Extracts
Soluble protein extracts of Ambrosia artemisiifolia L and Arte-
misia vulgaris L pollen were prepared according to Aina et al10 by
suspending 0.1 g of commercial pollen (Allergon, Ängelholm,
Sweden) in 1 mL of bidistilled sterile water that contained protease
inhibitor (1-mmol/L phenylmethylsulfonyl ﬂuoride). Samples were
incubated on a rotating drum for 2 hours at room temperature. The
soluble fraction was isolated by means of 2 centrifugations at
13,000 g for 10minutes at 4C and then stored at20C until use.
For 2-dimensional electrophoresis analysis, samples were pu-
riﬁed with a clean-up kit (Bio-Rad Laboratories, Hercules, Califor-
nia) and dissolved in isoelectric focusing (IEF) rehydration buffer
(7-mol/L urea, 2-mol/L thiourea, 2% [wt/vol] CHAPS (3-[(3-Chol-
amidopropyl)Dimethylammonio]-1-Propanesulfonate)), 20-mmol/
L Tris hydrochloride, pH 8.8, 20-mmol/L dithiothreitol (DTT), 0.5%
ampholyte mixture carrier, pH 3e10, 0.005% bromophenol blue).
Protein concentration was assayed according to Bradford11 using
bovine serum albumin as standard.
Two-dimensional Electrophoresis and Immunoblotting
IEF was performed on a 7-cm immobilized pH gradient strips
(Bio-Rad), providing a linear pH 4 to 7 gradient (for ragweed
extract) or a nonlinear pH 3 to 10 gradient (for mugwort extract).
Strips were rehydrated in 200 mL of rehydration buffer (7-mol/L
urea, 2-mol/L thiourea, 2% [wt/vol] CHAPS, 20-mol/L DTT, 0.5%
ampholyte mixture carrier, pH 3-10, 0.005% bromophenol blue)
that contained 100 mg of protein sample. Passive rehydration (up to
10 hours) and IEF were performed at 20C using a Protean IEF-Cell
(Bio-Rad Laboratories).
After the ﬁrst dimension separation, the IPG strips were equil-
ibrated for 15 minutes against 6-mol/L urea, 30% glycerol, 2% so-
dium dodecyl sulfate, 0.375 M Tris hydrochloride, pH 8.8, and 2%
DTT to resolubilize proteins and reduce disulfur bonds. The sulf-
hydryl groups were then blocked by substituting the DTT with 2.5%
iodoacetamide in the equilibration buffer for 15 minutes.
After equilibration, strips were placed on the top of vertical 10
9-cm  1.5-mm polyacrylamide gels (14% vol/vol). An agarose so-
lution (0.5% low melting agarose in running buffer) was loaded to
the top of the gel to lock strips, and electrophoresis was performed
at 4C in a Laemmle running buffer (25-mmol/L Tris hydrochloride,
pH 8.3, 192-mmol/L glycine, 0.1% sodium dodecyl sulfate).12
Gels were run in the electrophoresis chamber (Mini-Protean
electrophoresis system, Bio-Rad Laboratories) in parallel and used
for protein revealing or immunoblotting experiments. For protein
detection, gels were stained with colloidal Coomassie Blue G250
(0.1% Coomassie Blue G250, 170 g/L of ammonium sulfate, 34%
methanol, and 3% phosphoric acid). For immunodetection experi-
ments, gels were electroblotted (100 mA, overnight at 4C) onto
nitrocellulose membranes (0.45 mm, Bio-Rad Laboratories) by a
Trans-Blot cell apparatus (Bio-Rad Laboratories) that contained
transfer buffer (25-mmol/L Tris, 192-mmol/L glycine, and 20% [vol/
vol]methanol, pH 8.3). Nitrocellulosemembraneswere then blocked
with 5% (wt/vol) nonfat dry milk powder in TBS-T (20-mmol/L Tris,
150-mmol/L sodium chloride, and 0.1% [vol/vol] Tween 20, pH 7.5)
for 1 hour, rinsed in TBS-T 0.05%, and incubated with 1:10 diluted
serum. Bound IgE was detected with a horseradish perox-
idaseeconjugated goat anti-human IgE antibody (1:15,000 dilution,
Sigma-Aldrich, St Louis, Missouri) followed by ECL assay with a
commercial kit (Immun-Star Western C Kit, Bio-Rad Laboratories).
Table 1
Summary of the experimental results
Group Skin test Recombinant Art v 1 by ImmunoCAP Immunoblot IgE reactivity Primary sensitizer
Amb Art Natural Amb a 1 nArt v 1 nArt v 6
1 þ   High reactivity to all the isoforms   Ragweed
2 þ þ þ Predominant reactivity with 1.01 isoform þ þ Mugwort
3 þ þ  High reactivity to all the isoforms  þ Ragweed
4  þ þ No or negligible reactivity þ þ Mugwort
R. Asero et al. / Ann Allergy Asthma Immunol 113 (2014) 307e313 309Spots were visualized on an x-ray ﬁlm (Kodak, Rochester, New York).
Serum samples from 25 patients (8 Ambþ/Artþ, rArt v 1þ; 7 Ambþ/
Artþ, rArt v 1; and 10 Ambþ/Art) were tested.
LC-MS/MS and IgE-Binding Proteins Identiﬁcation
Immunoreactive bands were carefully excised from Coomassie-
stained 2-dimensional gels and submitted to in-gel trypsin diges-
tion according to Aina et al10 with minor modiﬁcations. The tryptic
fragments were analyzed by liquid chromatography tandem mass
spectrometry (LC-MS/MS). For the experiments, a linear ion trap
(LTQ Orbitrap XL; Thermo Fisher Scientiﬁc, Waltham, Massachu-
setts) high-resolution spectrometer, equipped with a reverse-
phase, high-performance liquid chromatography system, was used.
Protein identity was searched after peptide sequence attributions
with Global Proteome Machine software (http://www.thegpm.org)
with X!Tandem algorithm. The data used was created from down-
loads of 67 protein sequences from UniProt website (http://www.
uniprot.org) using the words pollen allergen Amb as query.
All peptides were analyzed using Basic Local Alignment Tool
Mass Spectrometry software (http://dove.embl-heidelberg.de/
Blast2/msblast.html) to obtain the putative protein identity. Pep-
tide sequences that were not identiﬁed through this database
search method were further analyzed for a de novo peptide
sequencing with Peaks Software (http://www.bioinfor.com).13
Immunoblot-Inhibition Assay
Immunoblot-inhibition experiments were performed according
to Asero et al.1 Each 1:10 TBS-T diluted serum sample was pre-
incubated overnight (4C) with increasing amounts (ranging from
2.5 to 10 mg of total proteins per 500 mL of diluted serum) of
ragweed or mugwort pollen extract. IgE reactivity was detected
before and after the absorption of serumwith the extract following
the protocol described above.Figure 1. Two-dimensional protein and allergen maps of ragweed pollen. A representativ
Coomassie G-250 (A) and the related 2-dimensional immunoblotting map obtained by u
show the 6 spots excised from polyacrylamide gel that after liquid chromatography tandem
1: Amb a 1.01; spot 2: mainly Amb a 1.01 but also 1.02, 1.04; spot 3: Amb a 1.01; and spResults
Patients, rAmb a 1 IgE Levels, and Reactivity to Amb a 1 Isoforms
A total of 34 patients were studied. Thirty-two (all from the area
of Milan) had strong IgE reactivity to rAmb a 1, with levels ranging
from 3.23 kU/L to greater than 100 kU/L (reference range,<0.35 kU/
L). On the basis of SPT with ragweed and mugwort extracts and on
ImmunoCAP assay results, patients were grouped as follows
(Table 1): (1) patients sensitized to ragweed but not to mugwort
pollen on SPT (Ambþ/Art; n¼10); (2) patients sensitized to both
mugwort and ragweed pollen in vivo (Ambþ/Artþ), showing
circulating IgE to Art v 1 on ImmunoCAP assay (n¼ 15) (in these
patients, rArt v 1 IgE levels ranged from 1.09 kU/L to 23.7 kU/L); (3)
patients sensitized to both mugwort and ragweed pollen in vivo
(Ambþ/Artþ), scoring negative to Art v 1 on ImmunoCAP (n¼ 7);
and (4) patients sensitized to mugwort but not to ragweed pollen
on SPT (Amb/Artþ; n¼2, both from Pordenone, an area where
ragweed is virtually absent).
The serum from each patient was tested for its reactivity to the
different Amb a 1 isoforms through a 2-dimensional immuno-
blotting analysis. Before this analysis, a reference 2-dimensional
map of Amb a 1 isoforms was developed to deﬁne the allergen
isoforms immunoreacting with the single serum sample. Figure 1
shows the 2-dimensional electrophoresis map of Ambrosia arte-
misiifolia pollen proteins fromwhich 6 of the most signiﬁcant spots
recognized by a pool of serum from patients with ragweed allergy
(Fig 1B) were excised and analyzed by LC-MS/MS. Immunoreactive
spots 1 and 3 were attributable to Amb a 1.01 isoforms. Spot 2 was
also mainly referable to an Amb a 1.01 isoform, although negligible
amounts of Amb a 1.02 and Amb a 1.04 were also detected. This
ﬁnding indicates a high similarity among these isoforms and a low
expression of Amb a 1.02 and Amb a 1.04 comparedwith Amb a 1.01
in mature ragweed pollen. In contrast, spots 4, 5, and 6 were all
referable to Amb a 1.03 isoforms.e 2-dimensional protein map of Ambrosia artemisiifolia pollen stained with colloidal
sing a pool of serum samples from patients allergic to ragweed (B) is shown. Arrows
mass spectrometry analysis were referable to the following Amb a 1 isoforms: spot
ots 4, 5, and 6: Amb a 1.03.
Figure 2. Serum reactivity to ragweed and mugwort proteins. Representative 2-dimensional immunoblots showing the IgE reactivity of the following 4 groups of patients’
serum samples with ragweed (A-D) andmugwort (E-H) soluble pollen proteins: group 1 (A, E): patients sensitized to ragweed but not tomugwort pollen (Ambþ/Art); group 2
(B, F): patients sensitized to both mugwort and ragweed pollen (Ambþ/Artþ), showing circulating IgE to Art v 1 on ImmunoCAP assay; group 3 (C, G): patients sensitized to
bothmugwort and ragweed pollen (Ambþ/Artþ), scoring negative to Art v 1 on ImmunoCAP; group 4 (D, H): patients sensitized tomugwort but not to ragweed pollen (Amb/
Artþ). Group 2 has a much more limited IgE reactivity to Amb a 1 isoforms than group 3.
R. Asero et al. / Ann Allergy Asthma Immunol 113 (2014) 307e313310Once the reference map was achieved, the differences in IgE
reactivity to Amb a 1 isoforms of the 34 single serum samples were
evaluated. The maps obtained for patients sensitized only to
ragweed (Ambþ/Art) showed all 6 immunoreactive spots char-
acterized in the reference map in all cases. A representative map
obtained for this ﬁrst group of patients is reported in Figure 2A.
Notably, the signal intensity was very high and similar among the
spots, suggesting that all these patients were sensitized to all the
main Amb a 1 isoforms expressed in ragweed pollen. In contrast,
serum samples from all the patients sensitized to both ragweed and
mugwort and positive to rArt v 1 on ImmunoCAP (Ambþ/Artþ, rArt
v 1þ) generally had a less intense reaction with Amb a 1 isoformsexcept for the isoforms present in spot 2 (ie, mainly Amb a 1.01; Fig
2B). The maps obtained for all the serum samples from the third
group of patients, also sensitized to both ragweed andmugwort but
negative for rArt v 1 on ImmunoCAP (Ambþ/Artþ, rArt v 1), were
similar and indistinguishable from the maps of the ﬁrst group of
patients (Ambþ/Art, Fig 2C). Finally, no Amb a 1 isoforms were
bound by IgE from serum samples of patients sensitized only to
mugwort (Amb/Artþ, Fig 2D).
To better understand the meaning of these differences in re-
actions to Amb a 1 isoforms and their possible relationship with
mugwort allergens, the reactivity of the same serum samples
against mugwort proteins was evaluated. Figure 2EeH, show
R. Asero et al. / Ann Allergy Asthma Immunol 113 (2014) 307e313 311representative 2-dimensional immunoblots. In keeping with
SPT results, no mugwort speciﬁc allergens were recognized by
Ambþ/Art patients’ serum samples (Fig 2E). On the contrary, at
least 2 isoforms of Art v 6 were recognized by all the serum samples
from the other groups of patients (Fig 2F, G, and H), and some
isoforms of Art v 1 were additionally recognized by serum samples
from both Amb/Artþ and Ambþ/Artþ, rArt v 1þ patients (Fig 2F
and H). The intensity of immunoreactive signals related to Art v 6
proteins was often higher than those related to Art v 1 allergen,
probably because of a negative effect of reduction and alkylation
processes, occurring during 2-dimensional analysis, on IgE reac-
tivity to Art v 1.14 However, the higher reactivity of Art v 6
compared with that of Art v 1 was also a characteristic of some
serum samples investigated in previous works.1,15
Immunoblot-Inhibition Assay
To determine whether mugwort and ragweed reactivity in the 2
groups of patients sensitized to both pollens (Ambþ/Artþ, rArt v
1þ and Ambþ/Artþ, rArt v 1) was the result of a cosensitization or
corecognition, 2-dimensional immunoblot inhibition experiments
were performed using mugwort and ragweed pollen extracts as
inhibitors. In Ambþ/Artþ, rArt v 1þ patients, preincubation of
serum samples with mugwort extract led to a complete inhibition
of IgE binding to all Amb a 1 isoforms (Fig 3A and B), whereas
preincubationwith ragweed extract caused only a partial reduction
in Art v 6 reactivity (Fig 3C and D), suggesting that primary source
of sensitization in all Ambþ/Artþ, rArt v 1þ patients examined was
mugwort. In Ambþ/Artþ, rArt v 1 patients, preincubation of
serum samples with mugwort pollen extract caused little or no
reduction in Amb a 1 signal (Fig 3E and F), whereas preincubation
of serum samples with ragweed pollen extract caused the complete
inhibition of IgE binding to Art v 6 isoforms (Fig 3G and H), sug-
gesting that for this group of patients the primary sensitizer was
ragweed. The same results were obtained by 1-dimensional
immunoblotting (data not shown). The overall results are sum-
marized in Table 1.
Discussion
The present study was started with a practical aim: to deﬁne
whether patients with seasonal symptoms of airborne allergy in
August and September and a double sensitization to ragweed and
mugwort pollen on SPT should undergo immunotherapy with 1 or
2 distinct pollen extracts. This problem was already addressed in 1
previous study,1 which found a probable cosensitization to ragweed
and mugwort. However, not all ragweed and mugwort allergens
were investigated on that occasion, and the recent information
coming from the work by Jahn-Schmid et al8 reporting a high de-
gree of cross-reactivity between the major ragweed pollen allergen
Amb a 1 and its homologous mugwort allergen Art v 6, along with
the ongoing observation that in the area of Milan mugwort hy-
persensitivity is virtually found only in ragweed-hypersensitive
individuals, prompted us to perform this study.
On the basis of both skin tests with pollen extracts and the
presence of IgE to rArt v 1, we divided patients into 4 subsets:
Ambþ/Art; Amb þ/Art, þ rArt v 1þ; Ambþ/Artþ, rArt v 1; and
Amb-/Artþ. Patients belonging to the ﬁrst subgroup were un-
questionably monosensitized to ragweed and recognized all iso-
forms of Amb a 1; these patients did not recognize any allergen in
mugwort pollen, indicating that they produced a multitude of
diverse IgE antibodies against epitopes speciﬁc of the various Amb
a 1 isoforms. In contrast, all the patients in the second subgroup
(Ambþ/Artþ, rArt v 1þ) recognized not only Art v 1 in mugwort
pollen but also Art v 6, some epitopes of which were mugwort
speciﬁc, whereas others were shared by Amb a 1, particularly by the
isoform Amb a 1.01. On the basis of the results of our inhibitionexperiments, these individuals appeared to be primarily sensitized
tomugwort, and their reactivity against ragweed extract on SPTand
to rAmb a 1 in vitro appeared as the result of the cross-reactivity
between Art v 6 and Amb a 1, the former being the primary
sensitizer. This ﬁnding is in agreement with the results of a previ-
ous study that found that Art v 6 can act as a primary sensitizer and
contains epitopes which cross-react with some Amb a 1 epitopes.8
The same study also found that Art v 6 cross-reactive epitopes are
few. This information helps to explain the 2-dimensional Amb a 1
isoform pattern typically produced by Ambþ/Art þ, rArt v 1þ pa-
tients’ serum samples, which was characterized by a signal
restricted to only one or a few Amb a 1 isoforms; this pattern was
probably the result of a primary sensitization to mugwort and only
subsequent corecognition of few isoforms of Amb a 1 by a small
fraction of IgE that were originally directed to Art v 6. Thus, we can
suppose that patients with IgE reactivity to Amb a 1, Art v 6, and Art
v 1 are ﬁrst sensitized to mugwort and only subsequently to
ragweed through a cross-reactive mechanism. This ﬁnding is in
keeping with the results of a Swiss epidemiologic study that found
that, in that area, the observed sensitization to Ambrosia is in most
cases a consequence of a primary sensitization to Artemisia.16 Of
course, in view of the limited number of serum samples tested, we
cannot exclude that some Ambþ/Artþ, Art v 1þ patients with a 2-
dimensional Amb a 1 isoform map similar to that of patients
monosensitized to ragweed (and thus showing a true cosensitiza-
tion to ragweed and mugwort) may exist. The existence of cosen-
sitized patients might be one of the reasons for the discrepancy
between our results and those reported by Asero and collabora-
tors.1 However, the lower protein concentrations of pollen extracts
that Asero et al1 used in their inhibition experiments compared
with those we used in our experiments could also represent an
additional explanation of the discrepancy between the 2 conclu-
sions. In fact, given the high variability of serum IgE type and
concentration, it is possible that, at least in some cases, the protein
concentrations used in the previous work were not sufﬁcient to
induce a complete IgE-binding inhibition. In support of this hy-
pothesis, most articles indicate the existence of signiﬁcant cross-
reactions between ragweed and mugwort allergens,7,8,17,18 and in
our opinion, at least in the Milan area, cross-reactivity is respon-
sible for the double sensitization in most cases. Only an increase in
the number of serum samples analyzed will allow a more complete
understanding of these phenomena.
Furthermore, our ﬁndings allowed us to discriminate between
Ambþ/Artþ, r Art v 1þ and Ambþ/Artþ, rArt v 1 patients; the
latter also reacted against both Art v 6 and Amb a 1 (but not with
Art v 1) and had a 2-dimensional Amb a 1 isoform map similar to
that of patients monosensitized to ragweed (Ambþ/Art). In this
case, our inhibition experiments revealed that the primary sensi-
tizer was the ragweed major allergen Amb a 1. In agreement with a
previous report that Amb a 1 is able to elicit a more diverse
repertoire of IgE than Art v 6, speciﬁc for Amb a 1 in most cases but
cross-reactive to Art v 6 in some others,8 the serum samples from
this third group of patients (Ambþ/Artþ, rArt v 1) reacted to all
Amb a 1 isoforms with a pattern that was indistinguishable from
that of serum samples from Ambþ/Art patients. Thus, our ex-
periments revealed that Art v 6 plays an important role in mugwort
allergy, that the cross-reactivity between Art v 6 and Amb a 1 may
be bidirectional, and that Art v 1 remains the only routinely avail-
able marker of a primary sensitization to mugwort. The inclusion of
Art v 6 in commercial diagnostic allergen panels for in vitro diag-
nosis would be useful in view of the existence of Amb/Artþ, Art v
1 patients who react against Art v 6especiﬁc, nonecross-reactive
epitopes.8 Nevertheless, in Ambþ/Artþ patients, the detection of
IgE to Art v 1 seems a fairly good marker to detect the primary
source of sensitization because most patients clinically allergic only
to mugwort react to Art v 1.18 Allergens other than Amb a 1 and Art
Figure 3. Two-dimensional immunoblot-inhibition assay. Representative pictures of reactivity of IgE contained in Ambþ/Artþ, recombinant Art (rArt) v 1þ patient serum
samples to ragweed allergens detected before (A) and after (B) the absorption of sera with mugwort pollen extract. Representative pictures of reactivity of IgE contained in
Ambþ/Artþ, rArt v 1þ patient serum samples to mugwort allergens detected before (C) and after (D) the absorption of sera with ragweed pollen extract. Representative
pictures of reactivity of IgE contained in Ambþ/Artþ, rArt v 1 patient serum samples to ragweed allergens detected before (A) and after (B) the absorption of sera with
mugwort pollen extract. Representative pictures of reactivity of IgE contained in Ambþ/Artþ, rArt v 1 patient serum samples to mugwort allergens detected before (F) and
after (G) the absorption of sera with ragweed pollen extract. IgE reactivity against ragweed allergens of Art v 1þ serum is completely inhibited by preabsorption with whole
mugwort extract, whereas preabsorption with whole ragweed extract has only a partial effect on IgE reactivity to mugwort allergens. In contrast, IgE reactivity against
mugwort allergens of Art v 1 serum is completely inhibited by preabsorption with whole ragweed extract, whereas preabsorption with whole mugwort extracts exerts no
effect on IgE reactivity to ragweed allergens.
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R. Asero et al. / Ann Allergy Asthma Immunol 113 (2014) 307e313 313v 6, such as Amb a 4, which is highly homologous to Art v 1,7 might
also play a role in sensitization to Compositae pollen and thus
represent a further confounding factor. However, in our 2-
dimensional immunoblotting, Amb a 4 was only a minor allergen
and was never detected by serum samples from Ambþ/Artþ, Art v
1þ patients. A similar result was also obtained by Asero et al.1 Thus,
Art v 1 can be considered a good marker of Artemisia sensitization
in Ambþ/Artþ patients, although in the absence of a 2-dimensional
immunomap of Amb a 1 isoforms, it is currently not possible to
completely exclude a cosensitization.
Altogether, this study found that cross-reactivity between Arte-
misia and Ambrosia pollen exists, is frequent (at least in the area of
Milan), is clinically relevant, and may be bidirectional. In clinical
practice, thebestmarkerof primary sensitizationpresentlyavailable
is Art v 1, although it is not sufﬁcient to discriminate between cor-
ecognition and cosensitization. In conclusion, by combining the
results of SPTandproteomic analyses,wewereable todetermine the
primary sensitizer in Ambþ/Artþ patients, discriminating between
cosensitization and corecognition. Unfortunately, this approach is
currently not applicable in the clinical practice; using the currently
available diagnostic tests, we found that Ambþ/Artþ patients
reactive to Art v 1 should be prescribed mugwort immunotherapy,
whereas Ambþ/Artþ patients not reactive to Art v 1 should be
prescribed ragweed immunotherapy because ragweed is probably
the primary sensitizer. Whether these patients should be also
treated with ragweed or mugwort immunotherapy, respectively,
remains an unanswered question in the routine clinical practice.
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